Madrigal Pharmaceuticals
MDGL
133 hedge funds and large institutions have $876M invested in Madrigal Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 49 increasing their positions, 43 reducing their positions, and 26 closing their positions.
67% more call options, than puts
Call options by funds: $9.87M | Put options by funds: $5.91M
14% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 43
1.57% less ownership
Funds ownership: 67.71% → 66.14% (-1.6%)
12% less funds holding
Funds holding: 151 → 133 (-18)
20% less capital invested
Capital invested by funds: $1.09B → $876M (-$218M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
69% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$38.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13M |
| 3 |
State Street
Boston,
Massachusetts
|
+$11.8M |
| 4 |
Goldman Sachs
New York
|
+$3.96M |
| 5 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$45.4M |
| 2 |
Citigroup
New York
|
-$13.9M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.1M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$9.56M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$7.7M |
MDGL Hedge Fund Activity: Q3 2021 in Review
133 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q3 2021, worth a combined $876M — down 20% from $1.09B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of MDGL and 8 opened new positions — a net loss of 18 holders — while 43 trimmed existing stakes and 49 added.
The largest buyer was Armistice Capital, adding an estimated $38.4M. The largest seller was Capital Research Global Investors, exiting entirely with an estimated $45.4M sold.
- 133 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q3 2021, down from 151 in Q2 2021.
- Funds reported $876M of Madrigal Pharmaceuticals stock for Q3 2021, down 20% quarter-over-quarter.
- 8 funds opened new Madrigal Pharmaceuticals positions in Q3 2021 and 26 closed out, a net change of -18 holders.
- The largest Madrigal Pharmaceuticals buyer in Q3 2021 was Armistice Capital, an estimated $38.4M added.
- The largest Madrigal Pharmaceuticals seller in Q3 2021 was Capital Research Global Investors, an estimated $45.4M sold.
Based on aggregated 13F filings for Q3 2021.